Procalcitonin in acute heart failure

Authors

  • George Michas Elpis General Hospital of Athens
  • Athanasios Trikas Elpis General Hospital of Athens

DOI:

https://doi.org/10.2015/hc.v13i1-4.844

Abstract

Acute heart failure (AHF) isa time critical disease and it is of outmost importance to identify the underlyingprecipitating factors as soon as possible as this can improve patient outcomes. Infection is such a significant factor. Procalcitonin (PCT), as a biomarker of bacterial infection, can be used in AHF patients to establish the diagnosis of concomitant bacterial infection. PCT can guide the early initiation of antibiotic therapy and provide prognostic information regarding AHF patients. This short review summarizes the current evidence on PCT use in AHF including the preliminary results of the IMPACT-BIC-18 trial. 

Downloads

Published

2019-03-21

Issue

Section

REVIEWS